Lilly looks to expand Cyramza's label into first-line NSCLC
Eli Lilly said it plans to initiate global regulatory applications mid-year seeking to expand the label of Cyramza ramucirumab to include first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have activating EGFR mutations. The pharma made the decision after reporting that Cyramza in combination with Tarceva erlotinib met the primary endpoint of improving progression-free survival (PFS) vs. placebo plus Tarceva in the Phase III RELAY trial.
The Eli Lilly and Co. (NYSE:LLY) drug is already approved in the U.S. and EU in combination with docetaxel to treat metastatic NSCLC in patients whose cancer has progressed on or after platinum-based chemotherapy...
BCIQ Company Profiles
BCIQ Target Profiles
Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)